Every 10-Q that BIOLARGO INC (BLGO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow BLGO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BLGO filings page.
BioLargo, Inc. reported sharply weaker results for the six months ended June 30, 2026. Total revenue was $2.36 million, down from $6.05 million a year earlier, as product revenue fell to $0.99 million from $4.81 million. Service revenue grew modestly to $1.36 million.
Gross profit declined to $1.13 million from $2.91 million, while operating expenses increased to $8.06 million, resulting in an operating loss of $6.93 million versus $3.66 million. Net loss was $7.41 million, with $5.05 million attributable to common shareholders. Cash used in operations was $5.97 million. At June 30, 2026, cash was $2.19 million, total assets $6.67 million, and total liabilities $9.40 million, producing a stockholders’ deficit of $2.73 million. Management disclosed a working capital deficit of $1.27 million and stated that current gross profits are not expected to fund operations for 2026, raising substantial doubt about the company’s ability to continue as a going concern absent increased revenues or additional financing.
BioLargo, Inc. reported Q1 2026 revenue of $1.115M, down sharply from $3.269M a year earlier, as product revenue fell from $2.803M to $577K. Service revenue rose modestly to $538K.
The company posted a net loss of $3.405M versus $1.921M in Q1 2025, driven by lower gross profit, higher operating expenses and increased interest and finance costs. Operating loss widened to $3.204M.
At March 31, 2026, BioLargo had cash and equivalents of $4.122M, current liabilities of $4.932M, and working capital of $513K, but total stockholders’ equity turned to a deficit of $187K. Management states that current-year gross profits will not fund operations and that these factors “raise substantial doubt” about the company’s ability to continue as a going concern without increased revenues and/or additional financing.
BioLargo (BLGO) reported a sharply weaker Q3 2025 as a major customer default triggered a large credit loss. Revenue was $1.103 million versus $4.351 million a year ago, with gross profit of $372,000. Operating expenses rose to $7.552 million, including a $3.849 million credit loss expense tied to impaired receivables and a note from a customer following contract and payment disputes now in litigation.
The quarter’s net loss was $7.244 million (vs. $1.060 million). Year to date, revenue was $7.148 million and net loss $11.047 million. Cash and equivalents were $4.546 million with current assets of $5.775 million and current liabilities of $3.451 million, yielding working capital of $2.324 million. The company stated that gross profits for 2025 will not fund operations and raised “substantial doubt” about its ability to continue as a going concern without additional revenue or financing.
Customer concentration remained high, with one customer representing 35% of Q3 revenue and 64% year to date. Cash from financing activities totaled $7.269 million for the first nine months, while operating cash used was $6.707 million. Shares outstanding were 313,762,657 as of November 12, 2025.